Conditions: Superficial Basal Cell Carcinoma
Keywords: Superficial Basal Cell Carcinoma Aldara
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 169
Healthy volunteers: no

Brief summary:
An open-label study to evaluate the safety and the ability of Imiquimod 5% cream, applied topically, to clear superficial basal cell carcinoma and to keep it clear for 5 years of follow-up.

Detailed description:
Evaluate the long-term sustained clearance rate, defined as the proportion of those subjects clinically clear of basal cell carcinoma (BCC) at the treated superficial BCC (sBCC) target tumor site at the 12-week posttreatment visit who remain clear during a 5 year follow-up period.

Arms:
arm 1: Aldara (imiquimod) cream 5% applied 7 times per week for 6 weeks

Interventions: intervention 1: Imiquimod 5% cream
Intervention descriptions: intervention 1: Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks

Protocol document: